IRF4 as an Oncogenic Biomarker for Hematological Malignancies
Journal Title: Journal of Oncobiomarkers - Year 2013, Vol 1, Issue 1
Abstract
The lymphocyte-specific transcription factor Interferon (IFN) Regulatory Factor 4 (IRF4) is crucial for lymphocyte development. Importantly, IRF4 has potent oncogenic and transforming properties, and its intimate interaction with lymphoid and myeloid malignancies has been increasingly recognized. In general, IRF4 exerts its function by transcriptionally regulating a pool of genes pivotal for cell development, oncogenesis and immune response. In clinical practice, IRF4 serves as an important prognosis and diagnosis marker for certain types of these malignancies. However, the oncogenic roles of IRF4 in most types of these malignancies and the molecular mechanisms underlying its interaction with them are largely not characterized. Accumulating evidence from cell culture shows that IRF4 regulates differential targets in distinct cancer contexts, depending on the “context-specific” co-regulator(s) associated with it in each setting. These complementary studies with in vitro cell culture systems are a necessary strategy which will provide molecular and mechanistic insights into the specific regulation and function of IRF4 in distinct cancer contexts, and may identify novel interventions specifically targeting IRF4 regulatory network for treatment. This review summarizes the evidence obtained from bench to bed showing the association of IRF4 with various types of hematological malignancies, with emphasis on molecular mechanisms underlying its regulation and its roles in these contexts.
Authors and Affiliations
Shunbin Ning
Keywords
Related Articles
- EP ID EP206202
- DOI 10.13188/2325-2340.1000003
- Views 89
- Downloads 0
Extracellular Domain Mutation of ErbB2 Status in Japanese Lung Cancer Patients
Purpose: The erbB pathway involves a family of tyrosine kinases and has contributed to resistance or sensitivity for chemotherapy in many tumor types. Somatic mutations of the erbB family receptor gene at kinase domain w...
KSHV Down-regulates Tropoelastin in Both an in-vitro and in-vivo Kaposi’s Sarcoma Model
Kaposi’s sarcoma (KS), a common cancer in individuals with HIV/ AIDS, lacks a curative therapy. Few studies have examined changes in extracellular matrix (ECM) protein profiles in the development of KS. Here we used an i...
11β-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis
Colorectal cancer (CRC) is a leading cause of cancer death, yet primary prevention remains the best approach to reducing overall morbidity and mortality. There is a clear molecular link between cyclooxygenase-2 (COX-2)-d...
Redefining the HER2 Oncobiomarker: A Relevant Case Report
In multiple studies anti HER2 therapy combined with chemotherapy demonstrated a marked improvement in disease free survival as adjuvant therapy and as treatment for metastatic breast cancer compared to chemotherapy alone...
Proteasome Subunit LMP2/β1i as a Biomarker for Human Uterine Mesenchymal Tumors
The proteasomal degradation pathway is essential for many cellular processes, including the cell cycle, regulation of gene expression, and responses to oxidative stress. The proteasome most exclusively used in mammals is...